Developer of microbial nitrogen fertilizers designed to replace synthetic nitrogen fertilizer. There may have been a 10-
Developer of microbial nitrogen fertilizers designed to replace synthetic nitrogen fertilizer. There may have been a 10-to-1 stock split at the last raise.
Agricultural Chemicals📍 Berkeley, CAFounded 2010
Current Valuation
$1.7B
as of 2021-Q3
UNICORN
QL Price
$1.2B
-29% vs last round
QuantLogix's current estimate for Pivot Bio, published 2026-09-06 — below the last disclosed round of $1.7B (2021-Q3).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$1.7B
2021-Q3
weight 0.03
Secondary market print
$1.2B
2026-06-27
weight 0.65
How this price has held up
No round has priced for Pivot Bio since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-06 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Pivot Bio, 2026-09-06 (7ce96c2ecd27dd97).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Pivot Bio going public?
No. Pivot Bio is private and has not filed to go public. There is no S-1 on file.
What is Pivot Bio's valuation in 2026?
Pivot Bio is valued at $1.7B as of 2021-Q3, set by its Series D ($430M, Jul 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Pivot Bio filed an S-1?
No public S-1 is on file for Pivot Bio.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2010
HQ
Berkeley, CA
Employees
307
Total Raised
$691.75M
Last Round
Series D — $430M (Jul 2021)
IPO Status
private
Fundraising Status
Series D · $430M · 5y 2mo ago
privateTotal raised $691.75M
Secondary Market
Implied price / share
$5.28
Last round price / share
$7.59
vs last round
-30.4%
Open interest
1
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series D
$430M
Jul 2021
—
$1.7B
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Pivot Bio — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-03. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
33% of roles posted in last 30d
Open roles
9
via greenhouse
Product-build share
11%
engineering, research, product, design
Trajectory
steady
go-to-market push — Only 11% of open roles build product — hiring is concentrated in sales/marketing/ops (6 of 9 open roles are other).
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
Associate ScientistCommercial Agronomist - HeartlandDirector, Data & Information ArchitectureDirector, Digital ProductGlobal Product Registration ManagerGlobal Product Registration Manager
Counted from Pivot Bio's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
CleanTechAgricultureAgTechBiotechnology
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q3. Refreshed quarterly.